{"id":519699,"date":"2021-07-29T07:05:25","date_gmt":"2021-07-29T11:05:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/blueprint-medicines-reports-second-quarter-2021-financial-results\/"},"modified":"2021-07-29T07:05:25","modified_gmt":"2021-07-29T11:05:25","slug":"blueprint-medicines-reports-second-quarter-2021-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/blueprint-medicines-reports-second-quarter-2021-financial-results\/","title":{"rendered":"Blueprint Medicines Reports Second Quarter 2021 Financial Results"},"content":{"rendered":"
\n

— Obtained FDA approval and launched AYVAKIT\u2122 (avapritinib) for advanced systemic mastocytosis —<\/h2>\n

— Expect topline data from Part 2 of registration-enabling Phase 2 PIONEER trial of AYVAKIT in non-advanced SM in mid-2022 —<\/h2>\n

— Initiated Phase 1\/2 trial of BLU-945 in EGFR-driven NSCLC and Phase 2\/3 HARBOR trial of BLU-263 in non-advanced SM —<\/h2>\n

— Announced strategic research collaboration with MD Anderson to accelerate development of BLU-222 —<\/h2>\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n CAMBRIDGE, Mass.<\/span>, July 29, 2021<\/span> \/PRNewswire\/ —\u00a0Blueprint Medicines Corporation (NASDAQ:BPMC) today reported financial results and provided a business update for the second quarter ended June 30, 2021<\/span>.<\/p>\n

\n

\n
\n \"Print\"
\n <\/a>\n <\/p>\n<\/p><\/div>\n

“In the second quarter, we achieved one of our foundational corporate goals, securing U.S. approval of AYVAKIT for advanced systemic mastocytosis, and the launch of this therapy is off to a great start with broad prescriber demand,” said Jeff Albers<\/span>, Chief Executive Officer of Blueprint Medicines. “In addition, we continued to progress our expanding clinical portfolio with the initiation of the Phase 1\/2 trial of BLU-945, the initiation of the Phase 2\/3 HARBOR trial of BLU-263 and the announcement of a strategic research collaboration with MD Anderson to accelerate the development of BLU-222, all of which exemplify the potential impact of our next wave of therapeutic candidates. This commercial and clinical progress, combined with our financial strength, provides a robust foundation for future growth as we look to address the needs of many more patients with cancer and hematologic disorders.” <\/p>\n

\n Second Quarter 2021 Highlights and Recent Progress<\/b>\n <\/p>\n

\n AYVAKIT\u2122\/AYVAKYT\u00ae (avapritinib): systemic mastocytosis (SM) and gastrointestinal stromal tumor (GIST)<\/b>\n <\/p>\n